- Gram (-) organisms resistant to other antibiotics
- IV intermittent infusion: over 30 minutes
< 1.2 kg:
- (0 - 4 weeks): 7.5 mg/kg/dose Q18-24H
1.2 - 2 kg:
- (0 - 7 days): 7.5 mg/kg/dose Q12-18H
- (> 7 days): 7.5 mg/kg/dose Q8-12H
> 2 kg:
- (0 - 7 days): 10 mg/kg/dose Q12H
- (> 7 days): 10 mg/kg/dose Q8H
- Dermatologic: rash
- Hematologic: anemia, eosinophilia, leukopenia
- Neuromuscular & skeletal: increased neuromuscular blockade when used with other neuromuscular blocking agents
- Otic: ototoxicity
- Renal: nephrotoxicity
- Renal: serum creatinine, urea, urine output
- Therapeutic drug levels:
- Trough (0 - 30 minutes before dose due): < 5 mg/L
- Peak (30 minutes after the end of a 30 minutes infusion): 20 - 30 mg/L
** When checking level, administer next dose as scheduled. Do not wait for levels to be reported unless otherwise advised
CHEO:
- Amikacin 250 mg/mL
- Take 1 mL (250 mg) and add to 24 mL D5W
- Final concentration: 10 mg/mL
TOH:
- Amikacin 250 mg/mL
- Take 1 mL (250 mg) and add to 49 mL D5W
- Final concentration: 5 mg/mL
- Solutions Compatible: dextrose, 0.45% NaCl, 0.9% NaCl, dextrose-saline combinations
- Y-site Compatible: acyclovir, cloxacillin, dexmedetomidine, fluconazole, furosemide, hydromorphone, midazolam, morphine, piperacillin-tazobactam, vancomycin
Incompatible: amphotericin B, heparin
** Due to the potential inactivation of aminoglycosides and antibiotics such as penicillins and cephalosporins, it is preferable to separate administration of these antibiotics by 30 - 60 minutes
-Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc.;2015
- American Society on Health-System Pharmacists (ASHP). Handbook on injectable Drugs. 19th Edition. Bethesda: ASHP 2017